Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma

Register now for this live, CME -certified symposium, featuring expert discussion of current status and future directions for immunotherapy in hepatocellular carcinoma.

During the live symposium, you will have multiple opportunities to interact with faculty through interactive patient case scenarios and dynamic question and answer sessions.

Thank you for your interest in attending this the Clinical Care Options’ (CCO) symposium, “Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma”, this that was originally scheduled as an in-person symposium in Madrid, Spain. Due to the global impact of COVID-19, ESMO organizers have decided to host the ESMO Annual Meeting in a virtual format.

As such, this live symposium will also now be held as a virtual live Webinar. Please note that the Webinar will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions as the in-person symposium. When participating in the live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To register, click one of the links below and once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services


Brief Overview of Immuno-Oncology in HCC
Bruno Sangro, MD, PhD

Immunotherapy Combinations in First-line Advanced HCC: Current Evidence and Ongoing Trials
Ghassan Abou-Alfa, MD

Immunotherapy Combinations in Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
Peter Galle, MD, PhD

Putting It All Together: Case Discussions
Panel Discussion

Final Thoughts and Audience Question and Answer Session


Date / Time
Event Details


Program Chair
Ghassan Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Peter Galle, Other

First Department of Internal Medicine
University Medical Center
Mainz, Germany

Bruno Sangro, MD, PhD

Professor of Medicine

Liver Unit and HPB Oncology Area
Universidad de Navarra
Pamplona, Spain

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging immune checkpoint inhibitor–based therapies for treatment of HCC.

Target Audience
This program is intended for global medical oncologists, hepatologists, and other healthcare providers who care for patients with HCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with HCC most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Evaluate clinical data on the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.